Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience

Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience

Pirfenidone and nintedanib are the only two drugs approved for the treatment of idiopathic pulmonary fibrosis (IPF). Both proved to be safe and well-tolerated in clinical trials, but real-world data and direct comparisons are scarce. This real-life study explored the safety profile of pirfenidone an...

Full description

Bibliographic Details
Main Authors: Stefano Levra, Giuseppe Guida, Andrea Elio Sprio, Flavio Crosa, Paolo Carlo Ghio, Francesca Bertolini, Vitina Carriero, Carlo Albera, Fabio Luigi Massimo Ricciardolo
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Biomedicines
Subjects:
pirfenidone
nintedanib
real-life
idiopathic pulmonary fibrosis
Online Access:https://www.mdpi.com/2227-9059/10/12/3229

Internet

https://www.mdpi.com/2227-9059/10/12/3229

Similar Items